A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00938587

Public ClinicalTrials.gov record NCT00938587. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will investigate the safety and efficacy of an investigational drug, PF-04171327 on the signs and symptoms of rheumatoid arthritis in patients that require glucocorticoids while on background methotrexate. This study will also look at the response of chemical and biological markers in rheumatoid arthritis patients. Lastly, this study will measure the PK (amount of drug in the blood) of methotrexate while patients may be taking PF-04171327.

Study identification

NCT ID: NCT00938587
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Pfizer; Industry
Enrollment: 86 participants

Conditions and interventions

Conditions

Rheumatoid Arthritis

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 7, 2009 (Actual)
Primary completion: Jul 29, 2010 (Actual)
Completion: Jul 29, 2010 (Actual)
Last update posted: Nov 22, 2023

2009 – 2010

United States locations

U.S. sites: 10
U.S. states: 5
U.S. cities: 8

Facility	City	State	ZIP	Site status
Anniston Medical Clinic, PC	Anniston	Alabama	36207	—
Pinnacle Research Group, LLC	Anniston	Alabama	36207	—
Allergy, Asthma, Arthritis and Lung	Daytona Beach	Florida	32114	—
Elite Research Institute	Miami	Florida	33169	—
Millennium Research	Ormond Beach	Florida	32174	—
Florida Medical Clinic, PA	Zephyrhills	Florida	33542	—
The Arthritis Center	Springfield	Illinois	62704	—
Premier Imaging Center	Bingham Farms	Michigan	48025	—
Quest Research Institute	Bingham Farms	Michigan	48025	—
Altoona Center for Clinical Research	Duncansville	Pennsylvania	16635	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00938587, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 22, 2023 · Synced Nov 10, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00938587 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →